Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
METTL8 orchestrates TFH cell differentiation through m³C-mediated TCF1 regulation in infection and cancer models
Jiaxi Song, Dan Cui, Jiabao Wang, Xuewei Qi, Jiaxin Ma, Haoyu Yu, Qing Liu, Jing Yang, Tengfei Hu, Xu Han, Handong Ma, Rentao Yu, Ying Dai, Xiaona Zhang, Qunfa Cao, Xiaoyuan Song, Bofeng Li, Lilin Ye, Hua Wang, Qizhao Huang, Jia Li, Fengyin Li
Jiaxi Song, Dan Cui, Jiabao Wang, Xuewei Qi, Jiaxin Ma, Haoyu Yu, Qing Liu, Jing Yang, Tengfei Hu, Xu Han, Handong Ma, Rentao Yu, Ying Dai, Xiaona Zhang, Qunfa Cao, Xiaoyuan Song, Bofeng Li, Lilin Ye, Hua Wang, Qizhao Huang, Jia Li, Fengyin Li
View: Text | PDF
Research Article Cell biology Oncology

METTL8 orchestrates TFH cell differentiation through m³C-mediated TCF1 regulation in infection and cancer models

  • Text
  • PDF
Abstract

T follicular helper (TFH) cells are critical for humoral immunity against infections and correlate with immunotherapy efficacy, whereas immune checkpoint inhibitor therapy can drive their aberrant expansion, underscoring the need to understand the regulators controlling TFH cell fate. However, the epitranscriptomic regulation of their differentiation remains poorly understood. Here, we identify the 3-methylcytosine (m³C) methyltransferase METTL8 as a key regulator of TFH cell differentiation in both viral infection and cancer. METTL8 was preferentially expressed in CXCL13hi TFH cells, and its deficiency impaired TFH differentiation and germinal center responses in the lymphocytic choriomeningitis virus infection model and following anti–PD-1 immunotherapy in tumor models. Mechanistically, METTL8 exerted dual functions: it bound and stabilized Tcf7 mRNA through m³C modification, and it interacted with TCF1 protein to regulate chromatin accessibility and 3D genome organization at key TFH-associated loci, including Cxcr5 and Il6ra. Notably, ginkgolic acid treatment suppressed TFH responses without compromising the antitumor efficacy of anti–PD-1 therapy, an effect associated with METTL8. Collectively, our findings identify METTL8 as an epitranscriptomic regulator linked to RNA modification, TCF1-associated transcriptional control, and chromatin architecture during TFH differentiation and suggest that modulation of this pathway may provide a strategy to tune TFH-driven immune responses.

Authors

Jiaxi Song, Dan Cui, Jiabao Wang, Xuewei Qi, Jiaxin Ma, Haoyu Yu, Qing Liu, Jing Yang, Tengfei Hu, Xu Han, Handong Ma, Rentao Yu, Ying Dai, Xiaona Zhang, Qunfa Cao, Xiaoyuan Song, Bofeng Li, Lilin Ye, Hua Wang, Qizhao Huang, Jia Li, Fengyin Li

×

Figure 4

METTL8 promotes TFH cell function.

Options: View larger image (or click on image) Download as PowerPoint
METTL8 promotes TFH cell function.
(A and B) Tumor growth (A) and surviv...
(A and B) Tumor growth (A) and survival (B) of MC38-bearing Mettl8fl/fl Cd4cre and littermate controls, treated with IgG or anti–PD-1 (n = 8/group). (C) Representative plots (left) and quantification (right) of GL-7+Fas+ GC B cells and CD138+IgDlo plasma cells (gated on B220+CD19+ cells) in the TdLNs of the above groups (n = 4–8/group). (D) Schematic of the adoptive transfer model: CD45.1+ Mettl8−/− or Ctrl Smarta CD4+ T cells were transferred into CD45.2+ Bcl6fl/fl Cd4cre recipients, followed by LCMV-Armstrong 24 h later, and analyzed at 14 dpi. (E and F) Representative plots (E) and quantification (F) of GC B cells and plasma cells in the spleens of the mice in D (n = 7–8/group). (G) Immunofluorescence of spleens from LCMV-Armstrong–infected Mettl8fl/fl Cd4cre mice and littermate controls at 8 dpi, indicating B cell follicle (green) and GC (red). Scale bars: 100 μm. (H) LCMV-specific IgG in serum of mice in D by ELISA (n = 5/group). (I) Serum samples were collected from Mettl8−/− or Ctrl Smarta cell–transferred mice at 4 dpi with LCMV‑Armstrong. Viral titers of the sera were quantified by qPCR using 2 independent primer pairs targeting the LCMV glycoprotein (GP) and nucleoprotein (NP) genes (n = 9–10/group). (J) Liver samples were collected from Mettl8−/− or Ctrl Smarta cell–transferred mice at 8 dpi with LCMV‑Armstrong. H&E staining showing inflammatory cell infiltration (arrows) in indicated groups. Scale bars: 200 μm (left), 50 μm (right). Data represent 2–3 independent experiments; mean ± SEM. P values were calculated using 2-way ANOVA (A), log-rank test (B), 1-way ANOVA (C), and 2-tailed Student’s t test (F, H, and I), *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts